These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 31036011)

  • 21. HIV prevalence, related risk behaviors, and correlates of HIV infection among people who use drugs in Cambodia.
    Sopheab H; Chhea C; Tuot S; Muir JA
    BMC Infect Dis; 2018 Nov; 18(1):562. PubMed ID: 30424727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
    Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J
    J Hepatol; 2020 Apr; 72(4):643-657. PubMed ID: 31785345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C virus prevalence, determinants, and cascade of care among people who inject drugs in Iran.
    Khezri M; Mirzazadeh A; Shokoohi M; Sharafi H; Ghalekhani N; Tavakoli F; Mehmandoost S; Mousavian G; Imani M; Kakavand-Ghalehnoei R; Komasi A; Gouya MM; Haghdoost AA; McFarland W; Karamouzian M; Sharifi H
    Drug Alcohol Depend; 2023 Feb; 243():109751. PubMed ID: 36621200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
    Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH
    Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-Risk Injection-Related Practices Associated with anti-HCV Positivity among Young Adults Seeking Services in Three Small Cities in Wisconsin.
    Rogers-Brown J; Sublett F; Canary L; Rein DB; Bhat M; Thompson WW; Vellozzi C; Asher A
    Subst Use Misuse; 2022; 57(5):665-673. PubMed ID: 35240921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased risk of HIV and other drug-related harms associated with injecting in public places: national bio-behavioural survey of people who inject drugs.
    Trayner KMA; McAuley A; Palmateer NE; Goldberg DJ; Shepherd SJ; Gunson RN; Tweed EJ; Priyadarshi S; Milosevic C; Hutchinson SJ
    Int J Drug Policy; 2020 Mar; 77():102663. PubMed ID: 31981949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.
    Alavi M; Grebely J; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S62-9. PubMed ID: 23884068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and correlates of HCV monoinfection and HIV and HCV coinfection among persons who inject drugs in Vietnam.
    Zhang L; Celentano DD; Le Minh N; Latkin CA; Mehta SH; Frangakis C; Ha TV; Mo TT; Sripaipan T; Davis WW; Quan VM; Go VF
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):550-6. PubMed ID: 25769097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique.
    Semá Baltazar C; Horth R; Boothe M; Sathane I; Young P; Chitsondzo Langa D; Condula M; Ricardo H; Dengo Baloi L; Cummings B; Schaad N; Gouveia L; Teodoro E; Raymond HF
    BMC Infect Dis; 2019 Dec; 19(1):1022. PubMed ID: 31791273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C antibody prevalence, correlates and barriers to care among people who inject drugs in Central California.
    Ozga JE; Syvertsen JL; Pollini RA
    J Viral Hepat; 2022 Jul; 29(7):518-528. PubMed ID: 35357738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
    Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
    Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).
    Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R;
    BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
    Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
    AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011-2018.
    Bardsley M; Heinsbroek E; Harris R; Croxford S; Edmundson C; Hope V; Hassan N; Ijaz S; Mandal S; Shute J; Hutchinson SJ; Hickman M; Sinka K; Phipps E
    J Viral Hepat; 2021 Oct; 28(10):1452-1463. PubMed ID: 34270172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review.
    Hajarizadeh B; Kairouz A; Ottaviano S; Ireland J; Willing A; Cunningham E; Webb P; Colledge-Frisby S; Wheeler A; Leung J; Tran LT; Price O; Vickerman P; Farrell M; Hickman M; Dore GJ; Bergenström A; Degenhardt L; Grebely J
    Lancet Glob Health; 2023 Dec; 11(12):e1885-e1898. PubMed ID: 37973339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study.
    Stone J; Artenie A; Hickman M; Martin NK; Degenhardt L; Fraser H; Vickerman P
    Lancet Public Health; 2022 Feb; 7(2):e136-e145. PubMed ID: 35012711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility.
    MacIsaac MB; Whitton B; Hubble A; Cogger S; Penn M; Weeks A; Elmore K; Pemberton D; Anderson J; Howard R; McKeever U; Papaluca T; Hellard ME; Stoove M; Wilson D; Pedrana A; Doyle J; Clark N; Holmes J; Thompson AJ
    Med J Aust; 2023 Apr; 218(6):256-261. PubMed ID: 36919230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
    Allen EJ; Palmateer NE; Hutchinson SJ; Cameron S; Goldberg DJ; Taylor A
    Int J Drug Policy; 2012 Sep; 23(5):346-52. PubMed ID: 22940142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs.
    E Williams B; Nelons D; Seaman A; Witkowska M; Ronan W; Wheelock H; Zaman A; Garcia J
    Int J Drug Policy; 2019 Oct; 72():138-145. PubMed ID: 30995968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Towards elimination of hepatitis C in Oslo: Cross-sectional prevalence studies among people who inject drugs.
    Opheim E; Dalgard O; Ulstein K; Sørli H; Backe Ø; Foshaug T; Couëssurel Wüsthoff LE; Midgard H
    Int J Drug Policy; 2024 Jan; 123():104279. PubMed ID: 38061225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.